[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201990305A1 - COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS - Google Patents

COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS

Info

Publication number
EA201990305A1
EA201990305A1 EA201990305A EA201990305A EA201990305A1 EA 201990305 A1 EA201990305 A1 EA 201990305A1 EA 201990305 A EA201990305 A EA 201990305A EA 201990305 A EA201990305 A EA 201990305A EA 201990305 A1 EA201990305 A1 EA 201990305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
mcl
bcl
combination
application
Prior art date
Application number
EA201990305A
Other languages
Russian (ru)
Other versions
EA039621B1 (en
Inventor
Эндрю Вэй
Дония Муджаллед
Джованна Помилио
Ана Летисия Мараньо
Оливье Женест
Одри Клаперон
Хайко Макке
Энсар Халилович
Дейл Портер
Эрик Моррис
Ючжэнь Ван
Снеха Сангхави
Пракаш Мистри
Original Assignee
Ле Лаборатуар Сервье
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье, Новартис Аг filed Critical Ле Лаборатуар Сервье
Priority claimed from PCT/EP2017/068453 external-priority patent/WO2018015526A1/en
Publication of EA201990305A1 publication Critical patent/EA201990305A1/en
Publication of EA039621B1 publication Critical patent/EA039621B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Комбинация, содержащая BCL-2 ингибитор и MCL-1 ингибитор, и их композиции и применения.A combination comprising a BCL-2 inhibitor and an MCL-1 inhibitor, and their compositions and uses.

EA201990305A 2017-06-09 2017-07-21 Combination of a bcl-2 inhibitor and a mcl1 inhibitor, uses and pharmaceutical compositions thereof EA039621B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762517252P 2017-06-09 2017-06-09
PCT/EP2017/068453 WO2018015526A1 (en) 2016-07-22 2017-07-21 Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
EA201990305A1 true EA201990305A1 (en) 2019-07-31
EA039621B1 EA039621B1 (en) 2022-02-17

Family

ID=67399647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990305A EA039621B1 (en) 2017-06-09 2017-07-21 Combination of a bcl-2 inhibitor and a mcl1 inhibitor, uses and pharmaceutical compositions thereof

Country Status (1)

Country Link
EA (1) EA039621B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008979B1 (en) * 2013-07-23 2015-07-24 Servier Lab NOVEL PHOSPHATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3015483B1 (en) * 2013-12-23 2016-01-01 Servier Lab NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Also Published As

Publication number Publication date
EA039621B1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2022004304A (en) Apoptosis-inducing agents.
BR112017023710A2 (en) histone deacetylase inhibitors and compositions and methods of use thereof
EA201890749A1 (en) ACETHYL-COA-CARBOXYLASE INHIBITORS (ACC) AND THEIR APPLICATION
CY1124338T1 (en) 3-PHOSPHOGLYCERATE DEHYDROGENATION INHIBITORS AND THEIR USES
EA201692437A1 (en) COMBINATION
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
EA201791992A1 (en) GRELIN-O-ACYLTRANSFERASE INHIBITORS
UY37560A (en) COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
EA201792000A1 (en) GRELIN-O-ACYLTRANSFERASE INHIBITORS
CY1122287T1 (en) COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
EA202091337A1 (en) MYST FAMILY HISTONACETYLTRANSFERASE INHIBITORS
EA201792262A1 (en) PIROGLUTAMAT VORTIOKSETINA
EA201792247A1 (en) HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS FOR THEIR USE
EA201892051A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MALIGNANT NON-FORMATION
ECSP19006687A (en) COMBINATION OF A BCL-2 INHIBITOR AND A MCL-1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS
CO2019007261A2 (en) Combination of an mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
EA201990305A1 (en) COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
EA201792093A1 (en) 2-TYOPYRIMIDINONES
EA201991623A1 (en) COMBINATION MCL-1 INHIBITOR AND TAXANIC COMPOUND, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
EA202091403A1 (en) 2-OXO-1-PYRROLIDINYLIMIDAZOTHIAZOLE DERIVATIVES
ECSP20017939A (en) PHARMACEUTICAL COMPOSITIONS
EA201991993A1 (en) APPLICATION OF PHENYLCREATIN AS A NOOTROPIC AGENT
UA115720U (en) 7-N-METHYLBENZYL-8-BENZYLIDENGIDRAZINOTEOPHILINE, WHICH HAS ANTI-HYPOXIC AND ANTIOXIDANT ACTION